AIRS — AirSculpt Technologies, Inc.

Summary of AirSculpt Technologies, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $33.4 million, down 15% year-over-year; same-store revenue declined 16%.
• Full Year Revenue: $151.8 million, a decrease of approximately 15.8% from fiscal 2024.
• Adjusted EBITDA: $2.5 million for Q4 (7.4% margin), up from $1.9 million in Q4 2024; full year adjusted EBITDA was approximately $15 million (10% margin), down from $21 million (12% margin) in fiscal 2024.
• Cash Position: $8.4 million as of December 31, 2025; reduced gross debt to $56 million.
• Debt Repayment: Paid down $19 million in debt during 2025, with a leverage ratio below 2.5x.

2. Strategic Updates and Business Highlights

• Operational Improvements: Focused on rebuilding and transformation in 2025, resulting in positive same-store sales growth beginning February 2026.
• New Services: Introduced skin tightening and skin removal procedures, with over 100 skin removal surgeries completed in Q4 2025.
• Marketing Enhancements: Implemented a new marketing strategy that includes connected TV and influencer engagement, contributing to improved volume trends.
• Talent Acquisition: Added experienced executives in finance, legal, and operations to strengthen leadership.

3. Forward Guidance and Outlook

• Q1 2026 Guidance: Expecting flat same-store sales, reflecting cautious optimism as trends improve.
• 2026 Revenue Outlook: Projected revenue range of $151 million to $157 million, indicating approximately 3% growth excluding the London center.
• Adjusted EBITDA Guidance: Expected to be in the range of $15 million to $17 million for fiscal 2026, incorporating benefits from improved revenue and cost-saving measures.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Continued decline in revenue and same-store sales year-over-year, indicating challenges in consumer spending.
• 10-K Filing Delay: Issues related to intercompany transactions and lease accounting led to a delay in the 10-K filing, raising concerns about financial reporting processes.
• Market Conditions: The ongoing geopolitical situation affecting helium plasma supply for skin tightening procedures could pose operational risks.

5. Notable Q&A Insights

• Seasonality Concerns: Management acknowledged that Q1 revenue may decline year-over-year, but emphasized a focus on consistent execution to meet full-year guidance.
• Core Business Trends: Body contouring and fat removal remain steady, with expectations of growth driven by new GLP-1-related procedures.
• Excisional Procedures Feedback: Positive early results from skin removal procedures, with plans to expand based on patient outcomes and surgeon feedback.
• Capital Allocation Strategy: Continued focus on debt reduction while investing in growth initiatives, with no new center openings planned for 2026.

Overall, AirSculpt Technologies is navigating a challenging environment with strategic initiatives aimed at stabilizing and growing the business, while also addressing operational and financial reporting issues.